Page 209 - Drug Class Review

Drug Effectiveness Review Project
Authors and Year: Tairot et al. 2000; Cummings et al. 2004, Galasko et al. 2004
Alzheimer classification: Mild-moderate
galantamine 8; 16; 24 mg/d placebo 77.1 76; 76.3; 77.7 62.2 64.2; 62.3; 67 93 94; 93; 91 17.7 18; 17.8; 17.7 29.4 27.8; 29.4; 29 Primary Outcome Measures: ADAS-Cog 11; CIBIC-plus Secondary Outcome Measures: ADAS-Cog 11 responders (improvement ≥ 4 points) and ADAS-Cog11 improvers (≥ 7 points); ADCS/ADL; NPI Timing of assessments: Baseline, weeks 4 and 13, and at 5 months Health Outcome Measures: Significantly less mean reduction in ADCS/ADL for 16 mg/d GAL (-0.7 vs. -3.8; P < 0.001) and • 24 mg/d GAL (-1.5 vs. -3.8; P < 0.01) compared to placebo Signif
Groups similar at baseline: Yes

Final Report Update 1 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% white): Other germane population qualities: MMSE • ADAS-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs